Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease

Author(s): Niki Katsiki*, George D. Dimitriadis, Dimitri P. Mikhailidis

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 16 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism.

In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, peripheral artery disease and non-alcoholic fatty liver in subjects with T2DM. The effects of antidiabetic drugs (e.g. metformin, pioglitazone, sulfonylureas, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors and insulin) on SUA concentrations are also reviewed.

Keywords: Serum uric acid, type 2 diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver, antidiabetic drugs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 16
Year: 2021
Page: [1941 - 1951]
Pages: 11
DOI: 10.2174/1381612827666210104124320
Price: $95

Article Metrics

PDF: 107